{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:28:14Z","timestamp":1793888894019,"version":"4.8.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the long-term safety and efficacy of sarilumab with\/without conventional synthetic (cs)DMARDs in RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The analyses evaluated two open-label extensions (OLEs): EXTEND and MONARCH OLE, which included patients from six randomized trials. Patients received sarilumab 200\u2009mg once every 2\u2009weeks (q2w) for at least 264\u2009weeks up to 516\u2009weeks (EXTEND: Sarilumab Monotherapy and Sarilumab + csDMARD groups) or for 276\u2009weeks (MONARCH OLE: Continuation and Switch groups). Primary endpoints included safety, immunogenicity and changes in laboratory parameters. Secondary endpoints included clinical signs and symptoms along with health-related quality-of-life (HRQOL) questionnaires.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Sarilumab Monotherapy (n\u2009=\u2009111), Continuation (n\u2009=\u2009165) and Switch (n\u2009=\u2009155) groups received sarilumab monotherapy, while the Sarilumab + csDMARD group (n\u2009=\u20091910) received sarilumab in combination with csDMARDs. Incidence of one or more treatment-emergent adverse events was 126 (Sarilumab Monotherapy group), 169 (Sarilumab + csDMARD group), 159 (Continuation group) and 159 (Switch group) events\/100 patient-years. Neutropenia was the most common adverse event. Neutropenia was not associated with an increased incidence of infections. Most neutropenia cases normalized on-treatment. Adverse events of special interests, such as malignancies, major adverse cardiovascular events, venous thromboembolism and gastrointestinal perforations, were rare. Immunogenicity was low and not associated with hypersensitivity reactions or discontinuations due to lack or loss of efficacy. Improvements in clinical signs and symptoms and HRQOL, observed during the initial blinded trials, were maintained throughout the OLE assessment period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-term sarilumab treatment with\/without csDMARDs in patients with RA revealed no new safety findings. Efficacy and HRQOL were maintained or further increased over the open-label assessment period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>EXTEND, ClinicalTrials.gov, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01146652, NCT01146652; MONARCH OLE, ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02332590, NCT02332590<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/kead062","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:40:41Z","timestamp":1675330841000},"page":"3268-3279","source":"Crossref","is-referenced-by-count":15,"title":["Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9-Universit\u00e4tsmedizin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University School of Medicine , Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Altoona Center for Clinical Research , Duncansville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chi","family":"Hu","sequence":"additional","affiliation":[{"name":"Sanofi , Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi , Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"van Hoogstraten","sequence":"additional","affiliation":[{"name":"Sanofi , Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella L","family":"Klier","sequence":"additional","affiliation":[{"name":"Sanofi , Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Metroplex Clinical Research Center , Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"2023100322113764800_kead062-B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2023100322113764800_kead062-B2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2023100322113764800_kead062-B3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.52.3.232","article-title":"Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity","volume":"52","author":"Madhok","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"2023100322113764800_kead062-B4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1109","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"2","author":"Smolen","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2023100322113764800_kead062-B5","doi-asserted-by":"crossref","first-page":"102884","DOI":"10.1016\/j.autrev.2021.102884","article-title":"Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis","volume":"20","author":"Takeuchi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023100322113764800_kead062-B6","author":"US Food and Drug Administration","year":"2017"},{"key":"2023100322113764800_kead062-B7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","article-title":"Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology","volume":"74","author":"Buch","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023100322113764800_kead062-B8"},{"key":"2023100322113764800_kead062-B9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/key361","article-title":"Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis","volume":"58","author":"Emery","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023100322113764800_kead062-B10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023100322113764800_kead062-B11","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023100322113764800_kead062-B12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40744-019-0157-3","article-title":"Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs","volume":"6","author":"Wells","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2023100322113764800_kead062-B13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023100322113764800_kead062-B14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-018-1614-z","article-title":"Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2023100322113764800_kead062-B15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch Pharm Res"},{"key":"2023100322113764800_kead062-B16","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023100322113764800_kead062-B17","first-page":"405","volume":"9"},{"key":"2023100322113764800_kead062-B18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of tocilizumab on neutrophil function and kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"2023100322113764800_kead062-B19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2023100322113764800_kead062-B20","article-title":"Reductions in absolute neutrophil count (ANC) with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety [abstract]","volume":"70(Suppl 10)","author":"Curtis","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2023100322113764800_kead062-B21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023100322113764800_kead062-B22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023100322113764800_kead062-B23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2011.537256","article-title":"Clinical safety of tocilizumab in rheumatoid arthritis","volume":"10","author":"Bannwarth","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"2023100322113764800_kead062-B24","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/acr.21764","article-title":"Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023100322113764800_kead062-B25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023100322113764800_kead062-B26","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023100322113764800_kead062-B27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am Heart J"},{"key":"2023100322113764800_kead062-B28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3899\/jrheum.180726","article-title":"Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: a 15-year longitudinal study","volume":"47","author":"Agca","year":"2020","journal-title":"J Rheumatol"},{"key":"2023100322113764800_kead062-B29","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023100322113764800_kead062-B30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.41122","article-title":"Impact of cumulative inflammation, cardiac risk factors, and medication exposure on coronary atherosclerosis progression in rheumatoid arthritis","volume":"72","author":"Karpouzas","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023100322113764800_kead062-B31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol Rev"},{"key":"2023100322113764800_kead062-B32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2023100322113764800_kead062-B33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023100322113764800_kead062-B34","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.39165","article-title":"Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients","volume":"67","author":"Liao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023100322113764800_kead062-B35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023100322113764800_kead062-B36","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023100322113764800_kead062-B37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13075-020-02344-3","article-title":"High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023100322113764800_kead062-B38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","article-title":"Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial","volume":"18","author":"Strand","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023100322113764800_kead062-B39","doi-asserted-by":"crossref","first-page":"e000416","DOI":"10.1136\/rmdopen-2016-000416","article-title":"Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response\/intolerance to tumour necrosis factor inhibitors","volume":"3","author":"Strand","year":"2017","journal-title":"RMD Open"},{"key":"2023100322113764800_kead062-B40","doi-asserted-by":"crossref","first-page":"e001017","DOI":"10.1136\/rmdopen-2019-001017","article-title":"Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension","volume":"5","author":"Burmester","year":"2019","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead062\/49278666\/kead062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/10\/3268\/51841440\/kead062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/10\/3268\/51841440\/kead062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T01:37:25Z","timestamp":1701826645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/10\/3268\/7023918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,2,2]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead062","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,2,2]]}}}